CStone Pharmaceuticals (HK:2616) has released an update.
CStone Pharmaceuticals has announced that the European Commission approved sugemalimab, marking the first approval in Europe of a China-developed anti-PD-L1 monoclonal antibody for first-line treatment of both squamous and non-squamous non-small cell lung cancer. The decision is backed by the positive results of the GEMSTONE-302 Phase III trial, which showed significant improvements in survival rates. The company is expanding its commercial partnerships globally and preparing to submit further Marketing Authorization Applications for new indications.
For further insights into HK:2616 stock, check out TipRanks’ Stock Analysis page.
